CBD bioavailability – what actually reaches your bloodstream

TL;DR

• Oral: 6-19 % (Millar 2018) – hepatic first-pass.
• Sublingual (oil under tongue, 60-90 s): 13-35 %.
• Inhalation (vape/flower): ~31 %, fastest onset.
• Food effect: fatty meal boosts oral AUC up to 5× (Birnbaum 2019).

Why oral bioavailability is so low

CBD is highly lipophilic (logP ≈ 6) and barely water-soluble after ingestion. It also undergoes hepatic first-pass metabolism (7-hydroxy-CBD via CYP2C19/CYP3A4). Net: 6-19 % of the dose reaches systemic circulation – hence clinical doses of 50-1500 mg/day.

How to improve absorption

• Hold oil 60-90 s under the tongue (venous route bypasses liver).
• Always take with a meal containing ≥15 g fat.
• Nano/liposomal formulations: 2-4× better AUC.
• Inhalation for fast onset (acute complaints).

Onset, duration and dosing windows in daily use

Bioavailability decides not only how much arrives but when. Inhalation peaks after 3–10 minutes and lasts 2–3 hours – useful for acute situations. Sublingual oils act after 15–45 minutes and last 4–6 hours. Capsules and edibles need 60–120 minutes but cover 6–8 hours, which suits a stable overnight level. In practice: for a morning-and-evening routine, combine sublingual and oral; for a targeted top-up, inhale. A fatty meal shifts the oral curve both up and later – so never compare a dose taken with food to one taken fasted.

Physiological factors influencing absorption

The bioavailability of cannabidiol is not a static variable, but depends heavily on individual physiological prerequisites. The state of the gastrointestinal tract, in particular the activity of digestive enzymes and the composition of bile, determines how efficiently lipophilic molecules such as CBD are emulsified. Individuals with impaired fat digestion or chronic inflammatory bowel diseases often absorb the active ingredient significantly less effectively. In addition, when administered sublingually, blood circulation in the oral mucosa influences how much active ingredient enters the bloodstream directly before the swallowing reflex sets in.

Another decisive factor is the enzymatic makeup of the liver, particularly the activity of the cytochrome P450 enzymes CYP3A4 and CYP2C19. Genetic variations mean that some people metabolise CBD extremely quickly, while others exhibit significantly higher active ingredient concentrations in the blood at the same dose. Age, body weight and general hydration status also alter the volume of distribution in adipose tissue, where CBD preferentially accumulates due to its lipophilicity and from where it is released back into the systemic circulation with a delay.

• Influence of individual enzyme activity in the CYP450 system on the intensity of the first-pass effect.
• Importance of intact bile production for micelle formation and emulsification of lipophilic substances.
• Influence of mucosal blood flow and salivary flow rate during sublingual application.
• Delayed release due to the storage of lipophilic CBD in the body's adipose tissue.

Influence of carrier oils and galenic excipients

Since pure CBD isolate is virtually insoluble in water, the carrier oil used in commercial formulations plays a critical role in bioavailability. Frequently used oils such as medium-chain triglycerides (MCT oil from coconut) or hemp seed oil serve not only as diluents but also influence the transport pathway in the body. Due to their shorter fatty acid chains, MCT oils are broken down more quickly in the small intestine and can be transported directly to the liver via the portal vein. This leads to rapid but potentially lossy metabolism by the enzymes located there.

In contrast, long-chain triglycerides, such as those found in olive oil or hemp seed oil, promote the formation of chylomicrons in the intestine. These lipid-protein complexes are not absorbed via the portal vein, but via the lymphatic system. As a result, a portion of the absorbed CBD bypasses the first pass through the liver, which can theoretically increase systemic bioavailability, albeit with a delayed onset of action. The choice of carrier oil is therefore a crucial galenic lever for specifically controlling the pharmacokinetic profile of a CBD product.

• MCT oil enables rapid absorption, but leads directly to first-pass metabolism.
• Long-chain triglycerides promote lymphatic transport and bypass hepatic passage.
• Influence of lecithins and other natural emulsifiers on micelle formation in the intestine.
• Stability of the active ingredient in the carrier oil to protect against oxidative degradation prior to ingestion.

Swiss quality standards and legal frameworks

In Switzerland, CBD products are subject to strict regulatory requirements, which also indirectly influence the consistency of bioavailability. For a product to be legally sold as a utility article or foodstuff, the total THC content must strictly be below 1 %. For manufacturers, this means that extraction and purification processes must be precisely controlled. Incomplete declarations or fluctuations in active ingredient content, which frequently occur with unregulated imports, lead in practice to unpredictable plasma concentrations in consumers.

Swiss authorities such as the BAG, the BLV and Swissmedic strictly monitor compliance with these limit values and quality standards. For medical applications, an exceptional permit from the BAG has no longer been required since August 2022, which facilitates access to standardized, magistral formulas. Compared to over-the-counter products, these medical preparations offer a guaranteed concentration of active ingredients and tested stability. This is essential, as impurities or degradation products can negatively affect absorption in the body.

• Strict compliance with the Swiss limit value of under 1 % total THC to avoid psychoactive effects.
• Quality assurance through monitoring by the BAG, Swissmedic and cantonal laboratories.
• Facilitated access to standardized medical preparations since the amendment to the law in August 2022.
• Importance of laboratory analyses to avoid heavy metals that could damage the intestinal barrier.

Risks and interactions with optimized absorption

An artificially or dietetically maximized bioavailability not only brings benefits, but also increases the risk of adverse drug interactions. If the plasma concentration of CBD rises drastically due to intake with a high-fat meal or through novel formulations, the cannabinoid increasingly blocks important liver enzymes. CBD acts as a potent inhibitor of CYP3A4 and CYP2C19. If other medications that are metabolized via the same pathways are taken at the same time, their active levels in the blood can rise dangerously.

In addition, a higher systemic load leads to greater stress on the liver. Although CBD is generally considered well-tolerated, clinical data at very high doses show the potential for an increase in liver enzyme levels. Consumers who attempt to maximize bioavailability through extreme measures should be aware of this risk. In the event of discomfort or suspected interaction, Tox Info Suisse offers a first point of medical contact in Switzerland under the emergency number 145.

• Increased blockade of CYP3A4 and CYP2C19 with sharply rising CBD plasma concentrations.
• Potential accumulation of concomitant medications such as blood thiners or antiepileptics in the blood.
• Risk of elevated liver values with long-term, uncontrolled, maximised absorption of the active ingredient.
• Importance of medical assessment via Tox Info Suisse (145) in the event of unexpected side effects.

FAQ